You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lung cancer mutation

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Mutation Consortium Protocol

Active, not recruiting
  • Adenocarcinoma of Lung, Stage IV
    • Aurora, Colorado
      University of Colorado Denver Cancer Center
    Jan 30, 2023

    Aumolertinib, Anlotinib, TP53 Trial (Aumolertinib,Anlotinib)

    Not yet recruiting
    • Aumolertinib
    • +4 more
    • (no location specified)
    Mar 8, 2023

    NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +32 more
    • (no location specified)
    Mar 30, 2023

    NSCLC Trial in Guangzhou (PLB1001)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Aug 15, 2023

    Non-Small-Cell Lung Cancer Trial in Guangzhou (PLB1004)

    Recruiting
    • Non-Small-Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong General Hospital
    Aug 25, 2023

    NSCLC, EGFR Gene Mutation, EGFR-TKI Resistant Mutation Trial (Nintedanib, gefitinib, erlotinib, afatinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • +2 more
    • Nintedanib, gefitinib, erlotinib, afatinib
    • (no location specified)
    Oct 2, 2023

    Advanced NSCLC Trial in Jinan (almonertinib)

    Recruiting
    • Advanced Non-small Cell Lung Cancer
    • Jinan, Shandong, China
      Degan Lu
    Sep 12, 2023

    NSCLC?EGFR Sensitive Mutation Trial in Bengbu, Changsha, Shanghai (MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100

    Not yet recruiting
    • Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
    • MCLA-129: 1500mg or 2000mg IV Q2W
    • Befotertinib: 75 mg or 100 mg Po QD
    • Bengbu, Anhui, China
    • +2 more
    Aug 28, 2023

    NSCLC Trial in Seoul (Lazertinib/Pemetrexed/Carboplatin)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    Mar 23, 2023

    NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

    Recruiting
    • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    • Combined therapy of anlotinib and aumolertinib
    • Kunming, Yunnan, China
      First Affiliated Hospital of Kunming University
    Oct 22, 2023

    EGFR Mutant Advanced NSCLC Trial (BBT-207)

    Not yet recruiting
    • EGFR Mutant Advanced Non-Small Cell Lung Cancer
    • (no location specified)
    Jun 16, 2023

    Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)

    Not yet recruiting
    • Non Squamous Non Small Cell Lung Cancer
    • EGFR Positive Non-small Cell Lung Cancer
    • Toripalimab plus Chemotherapy
    • (no location specified)
    Jul 28, 2023

    Learn About Tests Looking forGene Mutation in Lung Cancer in

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Beijing, China
      Department of Pathology, National Cancer Center/National Clinica
    Feb 24, 2023

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    NSCLC Trial in Busan (GDC-6036, Pembrolizumab)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Busan, Korea, Republic of
      Pusan National University Hospital
    Apr 3, 2023

    Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

    Completed
    • Non-small Cell Lung Cancer
    • (no location specified)
    May 8, 2023

    Advanced Cancer, Metastatic Cancer, Malignant Tumor of Lung Trial in Santa Rosa (Adagrasib)

    Recruiting
    • Advanced Cancer
    • +2 more
    • Santa Rosa, California
      Providence Medical Foundation
    May 2, 2023

    Solid Tumor, Adult, NSCLC, Advanced Cancer Trial (Adagrasib, nab-Sirolimus)

    Not yet recruiting
    • Solid Tumor, Adult
    • +4 more
    • (no location specified)
    Apr 24, 2023

    Radiomics for prEdiction of lunG cAncer biologY

    Active, not recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • PET/CT
    • Poitiers, France
      CHU Poitiers
    Apr 5, 2023

    Double-dose Furmonertinib in Treatment of Slow

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +3 more
    • (no location specified)
    Oct 31, 2023

    EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma Trial in Houston (Poziotinib)

    Recruiting
    • EGFR Exon 20 Mutation
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 12, 2022

    Aspirin in Combination With Trametinib and Dabrafenib

    Not yet recruiting
    • NSCLC
    • +4 more
    • Combind asprin with Trametinib and Dabrafenib
    • (no location specified)
    Aug 4, 2023

    NSCLC Metastatic Trial in Stockholm (Stereotactic body radiation therapy (SBRT), Temporary Stopping)

    Recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Stereotactic body radiation therapy (SBRT)
    • Temporary Stopping
    • Stockholm, Solna, Sweden
      Karolinska University Hospital
    Nov 9, 2023

    NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

    Recruiting
    • Non-Small Cell Lung Cancer
    • +2 more
    • Befotertinib + Icotinib placebo
    • Icotinib + Befotertinib placebo
    • Beijing, China
    • +2 more
    Sep 20, 2023

    Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)

    Recruiting
    • Non-squamous Non-small-cell Lung Cancer
    • +4 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Jan 8, 2023